专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014078731A3 CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS 审中-公开
公开(公告)号：WO2014078731A3
公开(公告)日：2014-05-22
申请号：PCT/US2013/070417
申请日：2013-11-15
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal
IPC分类号： C07K7/00 , A61K38/04 , C12N5/00 , A61P37/00
摘要： In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

2. 发明申请

WO2011163394A2 COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN 审中-公开
标题翻译：用于治疗神经性疼痛的COMPSTATIN模拟物
公开(公告)号：WO2011163394A2
公开(公告)日：2011-12-29
申请号：PCT/US2011/041492
申请日：2011-06-22
申请人： APELLIS PHARMACEUTICALS, INC. , FRANCOIS, Cedric , DESCHATELETS, Pascal
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal
IPC分类号： A61K38/08 , A61K38/10 , A61K38/16 , A61P25/00
CPC分类号： C07K7/52 , A61F13/532 , A61F13/535 , A61F2013/530554 , A61K9/0019 , A61K38/10 , A61K38/12 , A61K38/16 , A61K45/06
摘要： In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.
摘要翻译：在一些方面，本发明提供治疗需要治疗神经性疼痛的受试者的方法，所述方法包括向受试者施用化合物抑制素类似物。在一些实施方案中，所述化合物抑制素类似物肠胃外给药，例如静脉内给药。

3. 发明申请

WO2021011927A1 COMPLEMENT INHIBITOR DOSING REGIMENS 审中-公开
公开(公告)号：WO2021011927A1
公开(公告)日：2021-01-21
申请号：PCT/US2020/042676
申请日：2020-07-17
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： DESCHATELETS, Pascal , FRANCOIS, Cedric , GROSSI, Federico , JOHNSON, Patrick , SCHEIBLER, Lukas
IPC分类号： C07K14/47 , C07K17/08 , C07K7/08
摘要： Methods and compositions for inhibiting complement are described.

4. 发明申请

WO2019089653A1 TREATMENT OF DISORDERS 审中-公开
公开(公告)号：WO2019089653A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/058291
申请日：2018-10-30
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： FRANCOIS, Cedric
IPC分类号： A61K39/395 , C07K14/47 , G01N33/564
摘要： In some aspects, the disclosure provides methods of treating a subject in need of treatment for a chronic inflammatory disorder or autoimmune disorder. In some embodiments provided methods comprise administering an iC3b/C3dg/C3d inhibitor to the subject. In some embodiments the methods comprise administering an iC3b/C3dg/C3d inhibitor and/or a complement inhibitor to the subject, so that the subject is exposed to both. For example, in some embodiments, provided methods may comprise administering a complement inhibitor to a subject who has received one or more doses of an iC3b/C3dg/C3d inhibitor, or may comprise administering an iC3b/C3dg/C3d inhibitor to a subject who has received one or more doses of a complement inhibitor. Also provided are methods of identifying candidate agents for treatment of chronic inflammatory or autoimmune disorders, and/or of characterizing agents for use in such treatment.

5. 发明申请

WO2018187813A1 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS 审中-公开
公开(公告)号：WO2018187813A1
公开(公告)日：2018-10-11
申请号：PCT/US2018/026753
申请日：2018-04-09
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： GROSSI, Federico , DESCHATELETS, Pascal , FRANCOIS, Cedric , JOHNSON, Patrick , VEGA, Carolina
IPC分类号： A61F2/00 , A61K38/00 , A61K38/08 , A61K38/10
摘要： In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

6. 发明申请

WO2014028861A1 DETECTION OF HIGH RISK DRUSEN 审中-公开
标题翻译：检测高风险
公开(公告)号：WO2014028861A1
公开(公告)日：2014-02-20
申请号：PCT/US2013/055394
申请日：2013-08-16
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal
IPC分类号： C07K14/435 , G01N21/00 , C12Q1/37 , A61K38/12 , A61K38/04 , A61P27/02
CPC分类号： A61K49/0017 , C12Q1/37 , G01N2333/4716 , G01N2333/96433 , G01N2800/164 , G01N2800/50
摘要： In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided. In some aspects, presence of one or more high risk drusen in an eye indicates increased likelihood of developing AMD, GA, or advanced AMD or increased likelihood of rapid progression of AMD. In some embodiments, methods comprise detecting drusen containing or in close proximity to complement activation. In some embodiments methods comprise detecting one or more drusen having inflamed endothelium underlying or in close proximity thereto. In some embodiments methods comprise detecting eye-derived extracellular microvesicles, e.g., exosomes, in a body fluid. In some embodiments methods comprise detecting Th17 cells or a Th17 biomarker in a body fluid. In some embodiments the Th17 biomarker is a cytokine. Methods may be applied individually or in any combination. In some embodiments any of the methods further comprises treating a subject at risk of developing AMD, GA, or advanced AMD or at increased likelihood of rapid progression of AMD with a complement inhibitor. In some aspects, agents useful for performing one or more of the methods are described.
摘要翻译：在一些方面，提供在体内检测补体激活的方法，例如在眼睛中。在某些方面，提供了检测高风险玻璃疣的方法。在某些方面，在眼睛中存在一种或多种高风险的玻璃疣表明增加AMD，GA或晚期AMD的可能性增加，或AMD的快速进展的可能性增加。在一些实施方案中，方法包括检测包含或非常接近补体活化的玻璃疣。在一些实施方案中，方法包括检测具有下面或紧邻其中的发炎内皮的一个或多个玻璃疣。在一些实施方案中，方法包括在体液中检测眼睛衍生的细胞外微泡，例如外来体。在一些实施方案中，方法包括检测体液中的Th17细胞或Th17生物标志物。在一些实施方案中，Th17生物标志物是细胞因子。方法可以单独使用或以任意组合施用。在一些实施方案中，任何方法进一步包括治疗处于发展AMD，GA或晚期AMD的风险的受试者，或者以补体抑制剂快速进展AMD的可能性增加。在一些方面，描述了用于执行一种或多种方法的代理。

7. 发明申请

WO2012006599A2 COMPSTATIN ANALOGS FOR TREATMENT OF RHINOSINUSITIS AND NASAL POLYPOSIS 审中-公开
标题翻译： COMPSTATIN类似物治疗鼻窦炎和鼻息肉的疗效观察
公开(公告)号：WO2012006599A2
公开(公告)日：2012-01-12
申请号：PCT/US2011/043466
申请日：2011-07-08
申请人： APELLIS PHARMACEUTICALS, INC. , FRANCOIS, Cedric , DESCHATELETS, Pascal
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal
IPC分类号： A61K38/10 , A61K38/08 , A61P11/02 , A61P11/00
CPC分类号： C07K7/54 , A61K9/0043 , A61K38/08 , A61K38/10 , A61K38/12 , A61K45/06
摘要： In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administrering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray.
摘要翻译：在一些方面，本发明提供治疗需要治疗慢性鼻鼻窦炎或鼻息肉病的受试者的方法，所述方法包括向受试者施用补体抑制剂例如坎普他汀类似物。在一些实施方案中，补体抑制剂例如在鼻腔喷雾剂中鼻内施用。

8. 发明申请

WO2011137420A1 METHODS, ARTICLES AND KITS FOR ALLERGIC DESENSITIZATION VIA THE ORAL MUCOSA 审中-公开
标题翻译：方法，文章和通过口腔粘膜过敏症的病人
公开(公告)号：WO2011137420A1
公开(公告)日：2011-11-03
申请号：PCT/US2011/034731
申请日：2011-05-02
申请人： APELLIS PHARMACEUTICALS, INC. , FRANCOIS, Cedric
发明人： FRANCOIS, Cedric
IPC分类号： A61K8/00 , A61K8/18 , A61Q11/00
CPC分类号： A61K39/36 , A61C19/063 , A61K8/0208 , A61K8/9706 , A61K8/987 , A61K9/006 , A61K38/168 , A61K38/17 , A61K39/35 , A61Q11/00
摘要： Compositions and methods of use for desensitizing a subject to an allergen via regions of the oral mucosa are provided.
摘要翻译：提供了通过口腔粘膜区域使受试者对变应原脱敏的组合物和方法。

9. 发明申请

WO2021142171A1 TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 审中-公开
公开(公告)号：WO2021142171A1
公开(公告)日：2021-07-15
申请号：PCT/US2021/012561
申请日：2021-01-07
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： DESCHATELETS, Pascal , FRANCOIS, Cedric , GROSSI, Federico , MORRISS, Sharon , TAN, Elizabeth F.
IPC分类号： A61K9/00 , A61K38/12 , A61K47/60 , A61P7/00 , C07K16/18
摘要： Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising subcutaneously administering to the subject pegcetacoplan.

10. 发明申请

WO2019118938A1 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS 审中-公开
公开(公告)号：WO2019118938A1
公开(公告)日：2019-06-20
申请号：PCT/US2018/065870
申请日：2018-12-14
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： GROSSI, Federico , DESCHATELETS, Pascal , FRANCOIS, Cedric , JOHNSON, Patrick , VEGA, Carolina
IPC分类号： C07K7/06 , C07K7/50 , C07K7/64 , C07K14/47 , A61K38/04 , A61K38/12
摘要： In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式